New anticoagulants for treatment of venous thromboembolism

European Journal of Internal Medicine

Volumn 23, Issue 8, 2012, Pages 692-695

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Apixaban; Dabigatran; Deep vein thrombosis; Edoxaban; Pulmonary embolism; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED DENTISTRY; HAZARD RATIO; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; DRUG DESIGN; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84869095094     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.10.001     Document Type: Review

References (30)

1. J.A. Heit, L.J. Melton III, C.M. Lohse, T.M. Petterson, M.D. Silverstein, and D.N. Mohr Incidence of venous thromboembolism in hospitalized patients vs community residents Mayo Clin Proc 76 2001 1102 1110 (Pubitemid 33032387)
2. R.H. White The epidemiology of venous thromboembolism Circulation 107 2003 I4 I8
3. M.D. Silverstein, J.A. Heit, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 158 1998 585 593 (Pubitemid 28144815)
4. G.H. Guyatt, J.W. Eikelboom, M.K. Gould, D.A. Garcia, M. Crowther, and M.H. Murad Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e185S e194S
5. G. Agnelli, and C. Becattini Acute pulmonary embolism N Engl J Med 363 2010 266 274
6. T. Zhu, I. Martinez, and J. Emmerich Venous thromboembolism: risk factors for recurrence Arterioscler Thromb Vasc Biol 29 2009 298 310
7. P. Prandoni, F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, and R. Pesavento The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica 92 2007 199 205
8. R. Pesavento, E. Bernardi, A. Concolato, F. Dalla Valle, A. Pagnan, and P. Prandoni Postthrombotic syndrome Semin Thromb Hemost 32 2006 744 751 (Pubitemid 44623383)
9. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber Thrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S e494S
10. K.A. Bauer New anticoagulants Hematology Am Soc Hematol Educ Program 2006 450 456
11. J. Hirsh, M. O'Donnell, and J.W. Eikelboom Beyond unfractionated heparin and warfarin: current and future advances Circulation 116 2007 552 560 (Pubitemid 47450264)
12. M. Franchini, and P.M. Mannucci A new era for anticoagulants Eur J Intern Med 20 2009 562 568
13. P.M. Mannucci, and M. Franchini Old and new anticoagulant drugs: a minireview Ann Med 43 2011 116 123
14. J. Strangier, K. Rathgen, H. Stähle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
15. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
16. S. Schulman, A.K. Kakkar, S.M. Schellong, S.Z. Goldhaber, E. Henry, and P. Mismetti A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) ASH Annual Meeting, abstr #205 2011
17. S. Schulman, D. Baanstra, H. Eriksson, S. Goldhaber, A. Kakkar, and C. Kearon Dabigatran vs placebo for extend maintenance therapy of venous thromboembolism J Thromb Haemost 9 2011 22 [Abstract O-MO-037]
18. S. Schulman, H. Eriksson, S. Goldhaber, A. Kakkar, C. Kearon, and A.M. Kvamme Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism J Thromb Haemost 9 2011 731 [Abstract O-TH-033]
19. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
20. H.R. Buller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, and E. Minar Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
21. H.R. Buller, A.W.A. Lensing, and M. Prins Oral rivaroxaban for pulmonary embolism N Engl J Med 366 2012 2525 2527
22. N. Raghavan, C.E. Frost, Z. Yu, K. He, H. Zhang, and W.G. Humphreys Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
23. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism http://clinicaltrials.gov/ct2/show/NCT00643201 [Accessed August 14, 2012]
24. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism http://clinicaltrials.gov/ct2/show/NCT00633893 [Accessed August 14, 2012]
25. A.J. Camm, and H. Bounameaux Edoxaban: a new oral direct factor Xa inhibitor Drugs 71 2011 1503 1526
26. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study) http://clinicaltrials.gov/ct2/show/NCT00986154 [Accessed August 14, 2012]
27. W. Frank Peacock, M.M. Gearhart, and R.M. Mills Emergency management of bleeding associated with old and new oral anticoagulants Clin Cardiol 2012 10.1002/clc.22037
28. J.V. Freeman, R.P. Zhu, D.K. Owens, A.M. Garber, D.W. Hutton, and A.S. Go Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
29. J. Pink, S. Lane, M. Pirmohamed, and D.A. Hughes Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses BMJ 343 2011 d6333
30. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, and M. Silingardi Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 2012 1959 1967